PURPOSE: Primary @entity3038 (pPGS) is an extremely rare entity with only 25 cases reported in the English literature. The value of concurrent and adjuvant @entity2903 is not known in this group of @entity1 . METHODS: Five @entity1 of pPGS treated from 2006 to 2011 were included in this retrospective analysis. All @entity1 underwent maximal safe surgical resection. Adjuvant therapy included conformal radiation 60  Gy in 30 fractions (2  Gy daily for 5  days in a week) with concurrent @entity2903 75  mg/m(2) daily followed by six cycles of maintenance @entity2903 150-200  mg/m(2) (day 1 to day 5) every 4  weeks. We combined the survival data of 25 @entity1 (already published) and five of our @entity1 and analyzed them in terms of progression free survival (PFS) and @entity1349 ( @entity1349 ) using Kaplan-Meier method. RESULTS: Male to female ratio was 1:4 and median age was 12  years (range, 7-19  years). All but one @entity1 underwent gross total resection and four @entity1 completed adjuvant radiotherapy as well as concurrent and adjuvant @entity2903 . At a median follow up of 22.6  months (range, 0 to 45.3  months), two @entity1 were dead and two were alive without disease while one was lost to follow up. For the pooled data, estimated median PFS and @entity1349 of all 30 @entity1 reported in literature were 12 and 43  months, respectively. Two years PFS and @entity1349 rate for all @entity1 was 44.2 and 62.9  %, respectively. CONCLUSION: Adjuvant radiotherapy and @entity2903 is well tolerated and show an encouraging survival in pPGS.

@entity3038 treated with adjuvant radiotherapy and XXXX .

@entity3038 :: ('MESH:D018316', 'Disease') :: ['pediatric gliosarcoma'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity2903 :: ('MESH:C047246', 'Chemical') :: ['temozolomide'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity2903 :: (MESH:C047246,Chemical) :: ['temozolomide']
